TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 117 filers reported holding TCR2 THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 3.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $210 | -69.3% | 140 | -79.6% | 0.00% | – |
| Q4 2022 | $684 | -99.7% | 685 | +389.3% | 0.00% | – |
| Q3 2022 | $252,000 | -97.0% | 140 | -95.2% | 0.00% | – |
| Q2 2022 | $8,413,000 | -96.8% | 2,901 | -96.9% | 0.00% | – |
| Q1 2022 | $260,806,000 | -57.6% | 94,495 | -28.4% | 0.00% | -100.0% |
| Q4 2021 | $614,631,000 | +822.3% | 131,895 | +1584.3% | 0.00% | – |
| Q3 2021 | $66,642,000 | +17.5% | 7,831 | +126.6% | 0.00% | – |
| Q2 2021 | $56,713,000 | -89.0% | 3,456 | -85.1% | 0.00% | -100.0% |
| Q1 2021 | $513,669,000 | +362.3% | 23,264 | +547.7% | 0.00% | – |
| Q4 2020 | $111,101,000 | -9.0% | 3,592 | -40.2% | 0.00% | – |
| Q3 2020 | $122,144,000 | +1119.6% | 6,011 | +821.9% | 0.00% | – |
| Q2 2020 | $10,015,000 | -64.2% | 652 | -82.0% | 0.00% | – |
| Q1 2020 | $27,996,000 | -27.7% | 3,617 | +33.3% | 0.00% | – |
| Q4 2019 | $38,742,000 | +91.9% | 2,713 | +102.0% | 0.00% | – |
| Q3 2019 | $20,185,000 | +1708.7% | 1,343 | +1621.8% | 0.00% | – |
| Q2 2019 | $1,116,000 | – | 78 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $62,221,000 | 18.51% |
| MPM BioImpact LLC | 3,370,982 | $51,778,000 | 13.77% |
| Redmile Group, LLC | 1,765,188 | $27,113,000 | 0.50% |
| ArrowMark Colorado Holdings LLC | 1,356,010 | $20,828,000 | 0.22% |
| DAFNA Capital Management LLC | 46,183 | $709,000 | 0.20% |
| Artal Group S.A. | 350,000 | $5,376,000 | 0.15% |
| WFA of San Diego, LLC | 4,733 | $540,000 | 0.13% |
| Granite Point Capital Management, L.P. | 100,000 | $1,536,000 | 0.08% |
| HHLR ADVISORS, LTD. | 322,903 | $4,960,000 | 0.04% |
| SPHERA FUNDS MANAGEMENT LTD. | 30,000 | $461,000 | 0.04% |